Opaleye Management Inc. Catalyst Pharmaceuticals, Inc. Transaction History
Opaleye Management Inc.
- $390 Million
- Q2 2024
A detailed history of Opaleye Management Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 640,000 shares of CPRX stock, worth $13.9 Million. This represents 2.54% of its overall portfolio holdings.
Number of Shares
640,000
Previous 1,004,355
36.28%
Holding current value
$13.9 Million
Previous $16 Million
38.08%
% of portfolio
2.54%
Previous 3.9%
Shares
9 transactions
Others Institutions Holding CPRX
# of Institutions
295Shares Held
97MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$405 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$198 Million2.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.1MShares$176 Million0.0% of portfolio
-
State Street Corp Boston, MA6.03MShares$131 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$65 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.23B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...